Biotech Values

[p3analyze]

Just to clarify. I am not saying interim analysis affects the overall power. The study was designed to have 90% power with an interim analysis built in and therefore the overall power is fixed at 90%.

What I am pointing out is the CMO remark that 'the full power at the final analysis is 90%', which to me means 0 power was wasted on the interim analysis, hence a very conservative alpha spending at the interim analysis which the CMO characterized as being 'very little' earlier in the call.

I believe these remarks would contradict an OBF boundary which we know will spend at least 20-30% power (at an alpha of 0.013ish), leaving only 60-70% power instead of 90% for the final analysis.